BNET Industries
astrazeneca plc. - All News and Analysis
Pharma Roundup: Lilly's Prasugrel in Europe, AstraZeneca's $900 Million Deal, and More
EMEA backs Lilly's prasugrel, AZ pays $900 million for MAP partnership, Targanta lays off 85, Vertex's new hepatitis C drug may fetch $75,000. by John Maas
AstraZeneca to Target Nexium at Babies Under 1 Year Old
AstraZeneca has submitted a new drug application asking for approval to market Nexium for babies less than one year old. The company believes the drug is an appropriate short-term, second-line treatment for gastroesophageal reflux disease GERD. The application raises some interesting questions. It is well-known that babies throw up and...
Pharma Roundup: Glaxo, Cardio R&D, and Dynavax; Abbott, Ibis, and Isis; and More
GSK's new cardiovascular clinical trial and Dynavax partnership; Abbott's purchase of Ibis; AZ's potential Nobel conflict of interest; Charles Nemeroff's unending absurdity. by John Maas
Pharma Roundup: Bayer Boosts R&D, AstraZeneca Outsources, Titan Execs Leave, and More
Bayer boosts spending on research and development, AstraZeneca contracts with India's Infosys for IT support, Titan loses two execs, biotech acquisitions increase. by John Maas
AstraZeneca's Role in Nobel Prizes Is Questioned
UPDATE -- AstraZeneca failed to respond has now responded to BNET's request for comment, see below. The company also provided a statement to Pharmalot. The company confirmed its sponsorship of Nobel organizations but denied it had influenced the judges: "Because the Nobel Committee of Karolinska Institute, and not the Nobel companies,...
Pharma Roundup: Infinity and AstraZeneca Split, Schering & Merck's PR Blunder, and More
A fond farewell between Infinity and AstraZeneca, a dubious PR honor for S-P and Merck over Vytorin, Lilly's ImClone-related costs mount, generics cost less. by John Maas
The History of AstraZeneca's Mismarketing of Seroquel
AstraZeneca knew as far back as 2000 that Seroquel, its atypical antipsychotic, could cause diabetes in users. Since then, 15,000 consumers have sued the company. Documents describing AZ's early knowledge of Seroquel's risks surfaced in court, according to Bloomberg. In one document, AZ Global Safety Officer Wayne Geller concluded there...
Abraxis Split Closes Door on a Rocky Patch for AstraZeneca
The split between AstraZeneca and Abraxis over their copromotion of cancer drug Abraxane was expected among some Abraxis reps since August of this year. Now it's official. The end of the agreement comes as the patent on Casodex expires in April 2009 and the company this week saw mixed results...
Pharma Roundup: AstraZeneca and Teva Mend Fences, Barbara Ryan's M&A Speculation, and More
AstraZeneca and Teva settle a potentially-acrimonious patent battle. Barbara Ryan speculates on pharma M&A. EU criticizes "strategic patenting." Indonesia wants drug production facilities from Big Pharma. by John Maas
Pharma Roundup: Novartis Pipeline, AstraZeneca Layoffs, and More
Novartis pipeline, AstraZeneca layoffs, Merck's self-proclaimed goodness, lessons for pharma from Detroit. by John Maas
How AstraZeneca's U.S. Sales Reps Avoided the Current Round of Layoffs
AstraZeneca staff in the U.S. dodged a bullet this morning as the company announced 1,400 layoffs -- but none of them in America. The job losses will come instead in the U.K., Spain, Belgium and Sweden. AZ's explanation of the move was a masterpiece in cynical management-speak and news-burying. Its...
Pharma Roundup: Lawsuit for Roche, Teva Troubles for AstraZeneca, and More
Roche must pay in lawsuit, Teva aiming for AstraZeneca's customers, AstraZeneca's new U.S. president, and Novartis in Cambridge. by John Maas
Pharma Roundup: AstraZeneca's Crestor Success, Pfizer's Chantix Problems, and More
Highly encouraging results on AZ's Crestor, UK drug regulators echo Chantix suicide concerns, OTC drug marketers struggle, Lilly CEO highlights three "gorillas" dogging pharma. by John Maas
AstraZeneca's Cardiovascular Drug: Risks Up, Risks Down
Derek Lowe submits: AstraZeneca AZN took a pretty big risk in running a trial as big as the JUPITER one, but it seems to have paid off for them. As everyone has been reading, it appears that their Crestor rosuvastatin lowers the risk of cardiovascular events in patients with...
AstraZeneca Allegedly Recruits Tigger and Eeyore to Sell Seroquel
Some reps at AstraZeneca -- the ones urging their colleagues to use Tigger and Eeyore to sell the antipsychotic Seroquel -- just don't learn. Last year, AZ got itself embroiled in a federal investigation after one rep urged his colleagues to regard oncology docs' offices as "big buckets of money."...
Zacks Industry Rank Analysis Highlights: Abbot Laboratories, AstraZeneca, Chattem, Cubist Pharmaceuticals and ViroPharma
CHICAGO -- Zacks.com releases the latest Zacks Industry Rank. Stocks featured in this week's analysis includes Abbott Laboratories (NYSE: ABT), AstraZeneca (NYSE: AZN), Chattem (Nasdaq: CHTT), Cubist Pharmaceuticals (Nasdaq: CBST) and ViroPharma (Nasdaq: VPHM). To see the Zacks Industry Rank and the trend in earnings estimates revisions for more...
AstraZeneca and Columbia University Medical Center Sign Strategic Research Collaboration in Neurosciences; Focus on New Approaches to Treat Depression & Anxiety
WILMINGTON, Del. and NEW YORK, Oct. 15 /PRNewswire-FirstCall/ -- AstraZeneca and Columbia University Medical Center today announced a new research collaboration to examine how neurogenesis -- the creation of new neuronal cells - in adults might offer novel approaches to treating depression and anxiety. For more than...
Zacks Analyst Blog Highlights: AstraZeneca PLC, Phase Forward, Omnicom Group, Acorda Therapeutics and Digital River, Inc
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AstraZeneca PLC (NYSE: AZN), Phase Forward (NASDAQ: PFWD), Omnicom Group (NYSE:...
Pharma Roundup: AstraZeneca Wins Web Traffic, Genentech Wins "Best Employer," and More
AstraZeneca's Nexium is most-visited drug website, Genentech voted best place to work, fewer DDMAC warning letters over time, GSK execs talk research. by John Maas
Teva Sues AstraZeneca Over Crestor: $2.8 Billion on the Line
Teva, the generic maker, is suing AstraZeneca, the holder of the original Crestor patent, claiming that AZ is somehow infringing on rights Teva acquired to the drug back in March 2007. The Crestor patent isn't supposed to expire until 2016 -- well beyond the industry's looming patent...
Sort byClose
View by Content TypeClose
View by Related Tag Close
- Finance (44 results)
- FDA (37 results)
- Sales (30 results)
- Investment (26 results)
- stock (23 results)
- Novartis AG (19 results)
- Pfizer Inc. (18 results)
- GlaxoSmithKline Plc. (17 results)
- HEALTHCARE (15 results)
- Pharmaceutical Company (15 results)
- Agence France-Presse (14 results)
- Patient (14 results)
- collaboration (13 results)
- New York Stock Exchange (13 results)
- Blog (13 results)
- Software (13 results)
- Marketing (13 results)
- Bristol-Myers Squibb Co. (12 results)
- Merck & Co. Inc. (12 results)
- Sanofi-Aventis (11 results)
- agreement (11 results)
- Company (11 results)
- Government (10 results)
- Daily Mail (10 results)
- partnership (10 results)
- Strategy (10 results)
- Eli Lilly & Co. (10 results)
- R&D (10 results)
- Manufacturing (9 results)
- Benefits (9 results)
- MedImmune Inc. (9 results)
- John Maas (9 results)
- health care (9 results)
- Patent (8 results)
- Business Operations (7 results)
- Nasdaq Stock Market Inc. (7 results)
- Sales Strategy (7 results)
- Jim Edwards (7 results)
- Johnson & Johnson (7 results)
- life science (7 results)
- Biotechnology (6 results)
- British Petroleum Co plc (6 results)
- industry (6 results)
- AZ (6 results)
- Merger (6 results)
- London (6 results)
- Procter & Gamble Co. (5 results)
- Federal Government (5 results)
- Prudential Insurance Company of America (5 results)
- Acquisition (5 results)
Industry Transcripts by Seeking Alpha
-
Neogen Corporation F2Q09 (Qtr End 11/30/08) Earnings Call Transcript
on Jan 06, 2009about NEOG
-
Schiff Nutrition International, Inc. F2Q09 (Qtr End 11/30/08) Earnings Call Transcript
on Dec 16, 2008about WNI
-
AVANIR Pharmaceuticals F4Q08 (Qtr End 10/31/08) Earnings Call Transcript
on Dec 15, 2008about AVNR
-
Martek Biosciences Corporation F4Q08 (Qtr End 10/31/08) Earnings Call Transcript
on Dec 11, 2008about MATK
-
Peregrine Pharmaceuticals F2Q09 (Qtr End 10/31//08) Earnings Call Transcript
on Dec 10, 2008about PPHM